Taking The Pulse, A Health Care and Life Sciences Video Podcast | Episode 273: Navigating FDA Regulation for Life Sciences Companies with Christin Carey of Maynard Nexsen
Hot Flashes, Cold Policies: Legal and Benefit Strategies for Menopause — Hiring to Firing Podcast
PODCAST – 2026 To Do: HIPAA Compliance
2026 To Do: HIPAA Compliance
Health-E Law Podcast, Episode 24 | ViVE 2026: AI and the Future of Healthcare
Taking The Pulse, A Health Care and Life Sciences Video Podcast | Episode 272: Humanism and Transplant Care with Dr. Joseph Scalea of MUSC
AI in Healthcare: Five Healthcare AI Stories You Need to Know This Week - April 3, 2026
How to Stay HIPAA Compliant When Using Health Care Analytics
PBM Reform 2026: What Recent Legislation Means for the Industry
McDonald Hopkins Legal Diagnosis Podcast, Episode 8: Stark Law
Taking The Pulse, A Health Care and Life Sciences Video Podcast | Episode 271: Advancing Neurotrauma Treatments with Ken Webb of NeuroHope Therapeutics
AI in Healthcare: Five Healthcare AI Stories You Need to Know This Week – March 27, 2026
Health-e Law Podcast, Episode 23 | The Future of Brain Tech With Dr. Newton Howard
Hospice Insights Podcast - What’s New? CMS Provisional Period of Enhanced Oversight Application to “New” Hospices
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 270: Building a Future-Ready Workforce in Life Sciences with Daniel Grove of Lonza
State AGs in Action: Health Care Enforcement in 2026 – Speaking of Litigation Video Podcast
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 269: Investing in Distributed Healthcare with Gordon Maner of Frontline Healthcare Partners
Podcast - States Propose New Laws Affecting Healthcare Real Estate Investors and Owners
Hospice Insights Podcast - PPEO Playbook: The High-Stakes Game Hospices Can’t Afford to Lose
Podcast - Assessing the State of Healthcare Restructurings
Key Takeaways - HRSA has extended the deadline for comments on its proposed 340B rebate model pilot program to April 20, 2026. Covered entities have a limited window to submit detailed feedback on how the model would affect...more
Key Takeaways - Under the Section 232 national security authority, an additional 100% duty will apply to certain patented pharmaceuticals and associated ingredients, including active pharmaceutical ingredients and key...more
Over the past decade, the European Union has enacted a host of new legislation to protect the environment, promote sustainability, and tackle climate change, including the European Green Deal to new reporting and due...more
The UPC has been reshaping European patent litigation since its launch in June 2023. More than 480 patents have now been litigated in the court, and the number of actions is steadily increasing. Initially, major...more
The EU Commission published its 170-page proposal on revisions of the Medical Device Regulation (EU) 2017/745 (MDR) and the In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR) on December 16, 2025. After MDR and IVDR became...more
Pharmaceutical research and development is becoming more expensive and taking longer. Innovative AI scale-ups and platforms are addressing this by quickly accumulating vast datasets, but the larger companies that buy them...more
The life sciences and healthcare sector is a prominent target for shareholder activists. In 2025 a record 255 activist campaigns were launched worldwide, surpassing the previous high of 249 set in 2018, according to research...more
Thanks to its scientific skills base, growing prowess in AI and a policy environment that supports rapid clinical trials, China has become one of the world’s leading markets for pharmaceutical innovation. Here we explore how...more
The U.S. Food and Drug Administration’s fiscal year 2027 budget justification includes more than 20 legislative proposals spanning drug and biologic approval pathways, supply chain oversight, advertising standards and...more
Congress’ two-week recess has officially ended, with the House returning tomorrow and the Senate back in session today. Both chambers are returning to full agendas, with attention focused on budget hearings, ongoing...more
On April 2, 2026, the U.S. Environmental Protection Agency and Department of Health & Human Services released a draft Sixth Contaminant Candidate List, or “CCL 6,” for public comment....more
In its March 2026 draft guidance, the US Food and Drug Administration (FDA) outlined its current thinking on how drug and certain product manufacturers should approach Form 483 responses to inspectional observations issued at...more
Two recent announcements from the Centers for Medicare & Medicaid Services (CMS) continue to signal the Trump administration’s approach to the Medicare Advantage (MA) program, building on trends first seen in the Contract...more
Many healthcare providers assume their technology contracts are static—negotiated once and largely administrative thereafter. That assumption is increasingly risky. Vendors are rapidly embedding artificial intelligence (AI)...more
The New York Times reported on March 31, 2026 that the U.S. Food and Drug Administration is moving to lift its ban on more than a dozen injectable peptides that were restricted in 2023 over significant safety concerns. The...more
Employers sponsoring wellness programs including tobacco surcharges have faced a growing wave of ERISA class action litigation over the past several years. These lawsuits primarily challenge whether such programs comply with...more
On March 27, 2026, the Food and Drug Administration (“FDA”) held a public meeting entitled “Exploring the Scope of Dietary Supplement Ingredients.”...more
In a notable back-to-back set of releases, the Financial Crimes Enforcement Network first issued a March 30, 2026 advisory urging financial institutions to identify and report suspicious activity tied to health care fraud...more
We have recently released the second edition of our Life sciences and healthcare insights report, where our global team explore the most important commercial, legal and regulatory issues facing life sciences and healthcare...more
On March 20, 2026, the White House issued a National Policy Framework (the “Framework”) for artificial intelligence (AI) that addresses six key objectives. The Framework calls on Congress to establish a federal policy...more
There has been a recent and sudden uptick in enforcement from federal agencies against medspa prescribers. Specifically, the Department of Justice (DOJ) recently indicted a licensed osteopathic physician for allegedly...more
The Illinois Genetic Information Privacy Act, (GIPA) has recently become one of the plaintiff class action bar’s favorite causes of action. GIPA regulates the collection, use, disclosure, and storage of genetic information....more
This is the fifth in a six-part series on incentive design, deal structure, and how these issues surface in transactions and enforcement. Other relevant topics will be discussed in our upcoming presentation, Physician Owner...more
The US Environmental Protection Agency (EPA) on April 2, 2026 published the draft Sixth Contaminant Candidate List (CCL 6), which for the first time identifies both microplastics and pharmaceuticals as contaminant groups for...more
Employers will soon be obligated to provide employees with severance benefits if they want to have an enforceable noncompete in Virginia and they also will be prohibited from entering into noncompetes with health care...more
